Clinical trial
A Study of ABT-263 in Participants With Relapsed or Refractory Chronic…
NCT00481091 · AbbVie, Industry · Completed
Key facts
| NCT number | NCT00481091 |
|---|---|
| Title | A Study of ABT-263 in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia |
| Official title | A Phase 1/2a Study Evaluating the Safety, Pharmacokinetics, and Efficacy of ABT-263 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia |
| Lead sponsor | AbbVie, Industry |
| Collaborators | Genentech, Inc. Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Chronic Lymphocytic Leukemia |
| Intervention type | Drug |
| Interventions | ABT-263 |
| Enrollment | 60 |
| Start date | Jul 25, 2007 |
| Primary completion | May 12, 2022 |
| Completion | May 12, 2022 |
| First posted | Jun 1, 2007 |
| Last update posted | Jun 13, 2023 |
| Countries | Australia, Germany, United Kingdom, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: